HLB Inc
KOSDAQ:028300
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
HLB Inc
Income from Continuing Operations
HLB Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HLB Inc
KOSDAQ:028300
|
Income from Continuing Operations
-₩235.4B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Income from Continuing Operations
₩47.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
6%
|
|
|
SD Biosensor Inc
KRX:137310
|
Income from Continuing Operations
-₩98.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Income from Continuing Operations
₩17.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Income from Continuing Operations
₩46.4B
|
CAGR 3-Years
33%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
I
|
Interojo Co Ltd
KOSDAQ:119610
|
Income from Continuing Operations
₩12.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
HLB Inc
Glance View
Nestled in the bustling corridors of international commerce, HLB Inc. stands as a dynamic player in the healthcare logistics and biomedical sector. Over the years, it has carved a pivotal niche through its adept coordination of high-stakes operations that drive the backbone of medical supply chains. At the heart of its operations are innovative solutions that ensure medical products — ranging from essential pharmaceuticals to state-of-the-art medical devices — navigate smoothly from manufacturers to healthcare providers. This meticulous orchestration not only bolsters the efficiency of healthcare delivery but also makes HLB Inc. an indispensable ally in the realm of modern medicine. The company’s revenue model thrives on the intricate balance of logistical prowess and cutting-edge biomedical services. By leveraging strategic partnerships and technology-driven process improvement, HLB Inc. delivers unparalleled value in both time efficiency and cost-effectiveness. Service contracts with healthcare institutions and governmental bodies serve as significant revenue channels, as the company deftly integrates its logistics network with client demand. Simultaneously, its investments in research and development keep HLB Inc. at the forefront of healthcare innovation, providing an array of bespoke solutions that cater to the evolving landscape of healthcare needs. This dual approach not only solidifies its financial performance but also reflects a commitment to advancing the frontiers of healthcare accessibility and reliability.
See Also
What is HLB Inc's Income from Continuing Operations?
Income from Continuing Operations
-235.4B
KRW
Based on the financial report for Dec 31, 2025, HLB Inc's Income from Continuing Operations amounts to -235.4B KRW.
What is HLB Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-22%
Over the last year, the Income from Continuing Operations growth was -118%. The average annual Income from Continuing Operations growth rates for HLB Inc have been -34% over the past three years , -22% over the past five years .